THat article says nothing about BTX--and even less about burn rate until positive revs. And so, even less about positive revs by GAAP, not AK's accounting tricks.
Great post. It illuminates the accounting dodge. " if the amount of cash distributed is less than BTX's basis in the stock of the subsidiary." Which is to say---more accounting dodge. To get that done, holders of the common get diluted.
So--1 year before the next round of dilution.
Purchased leftovers that the Japanese didn't want.
"Detection" products already priced in.
How much marketing expense to get them to 5% mkt share?
When will they generate $1k GAAP net over incurred expense?
"Subsidiaries" cost around $50 apiece to declare. And are nothing but an accounting dodge .
In addition to you being a liar and a fraud--thereby making you the ideal BTX "long", you're doing a great jopb of showing new readers that "longs" refuse to answer simple questions about the stock--not the whizbang.
If you're "convinced" I'm short this dog in any shape, way, fashion, including as part of any index or fund in which it might be contained, there's an easy $50,000 waiting for you.
So--back to what year will it be when "Renevia" is $1k GAAP positive?
What does that article ab out blood have to do with BTX? If there's any at all, you can easily post the relevant link or keywords.
BTW, notin that BTX pays Weill to do certain research for it research, without specifying exactly what is not a link. It's just more smoke & mirrors.
The only question out of all that is what per cent of patents coming from that research kick royalties back to BTX....
Oh--and how many years before an IND resulting from this finding is filed.
And who owns what parts of the entity that does the filing.
Other than that, the post is off-topic.
REvenue is a good thing? Dang straight. So--how much a share come from this over the next two years??
So--what's the download price for the ap? That's the only info that means anything to the stock--except as another way to round up retail road kill to buy T-shares.
This "agreement" will yield $1k in GAAP revenues in what year? 2024? All that agreement does is combine two databases.
When BTX bought what it now calls LifeMap, it was generating around $65 a year--paying the salary of the guy who developed the database. Has that doubled after 5 years? Anything come from Mikey buying a seat license for $750K to the European version that's been runnnig since about 2002?
Not go to Japan? To the degree that any of that stuff works, an actual player like Pfizer will have it on the table as soon as the FDA clears it. Anf you'll have it as soon as your insurer covers it---since you are evidently not wealthy enough to travel.
OK--So what's 10x what BTX claims is book value? Around $2.
Which, for the insiders and cronies, is a great price, given their actual net basis.
And this dog has no way of selling for more than around 4x book except to gameboys and retail road kill.
And Take Under Al is called that for a reason.
If you were a "man of science" you'd know that the "future" doesn't talk.
Pretedning for a moment that what you said has any sense in it, then yes, it's in the right direction. So were those of the Oregon Trail.
In the real world, where actrual science happens, BTX is an equity, not an ideology.
"Unless - ok sure - $100M shelf offering is a product " According to every 10K since 1992 it is the principal product. Although the subtle death spiral written into the $100 million unspecified tranche looks much more like TakeUnder Al than Peabody. (Remember how AK has been paid over $1mm cash since 96 by BTX to pump BTX? That is, his net basis is around $0.00 or below. )
Anybody who likes this dog can tgrade it into accumulation towards that same net basis.
Laws of a baltbear: "Trust mgt to the degree your basis is like theirs."
Hi there lying piece of filth. There's $50,000 waiting for anyone who can established that I ever was long fo0r alter delivery on this dog except as covered calls, or its constituent membership in ^rua and ^rut. -- or had any client who was in the dog either way, except as part of an index. Period.
"Friend" ??? The odds on that went to zero when you ran from a discussion of when the rooster comb soup thar BTX calls "Renevia" would be at $1000 positive GAAP net cash flow over the money dumped into it.
Your immediate change of subject showed you to be a shill.
Yeah--for Peabody--who gets a quarter million for being AK's gopher....
" he will receive a consulting fee of $15,000 per month for services to BioTime and OncoCyte. The Consulting Agreement will terminate on November 18, 2016, or earlier upon: (a) the death or disability of Mr. Peabody;(b) thirty days written notice from Mr. Peabody which may be given after February 28, 2015; (c) written notice from BioTime given at any time after the total payments received by Mr. Peabody from LifeMap Solutions and under the Consulting Agreement total $221,500;
There go all the "REnevia " profits for the next 5 years.
Total thumbs down. BTX abandoned that market, and said so in the 10K of 2011 or so.
But the recent surge of interest in transhumanists who are known Alcor clients no doubt makes this kind of pumping look good again.
Yup...And whatever earnings from the i/p ever arrives will accrue to AK, Neal, and Garfies--while the acccumulated shareholder deficit will go to retail road kill.
And this dog is down ~25% since you started saying that at around 4 3/8.
No stock is ever "worth" more than its realisable future income, although people refusing to learn that means there are plenty of opportunities to trade into accumulation.
The " nice try tho Noah" is false ever since he turned tail and ran when asked about revenues from "Renevia."
(By the way, Biotime has a long history of having employees posting to YHOO, on both public and proivate groups.
At three times what BTX says is the value of its intellectual property, that would be right around 1 3/8 a share.
At 2x, it's under a buck.
That's a net decline per share in the past 3 years.
In the meantime, the T/A is bearish, while the F/A continues at way overpriced.